Molnupiravir is an antiviral agent that inhibits viral RNA polymerase replication. Molnupiravir is administered orally in the treatment of COVID-19.

Magnitude of Teratogenic Risk to Child Born After Exposure During Gestation: UNDETERMINED

Quality and Quantity of Data on Which Risk Estimate is Based: NONE

Comments: NONE

Summary of Teratology Studies:

MAJOR CONGENITAL ANOMALIES

No epidemiological studies of congenital anomalies among infants born to women who were treated with molnupiravir during pregnancy have been reported.

ANIMAL TERATOLOGY STUDIES

Animal teratology studies of molnupiravir conducted by the manufacturer have not been published in the peer-reviewed literature, although they indicate the possibility of fetal toxicity in more than one species.

Selected References:
(Each paper is classified as a review [R], human case report [C], human epidemiological study [E], human clinical series [S], animal study [A], or other [O].)

None available.